Li Xu, M.D., is a Venture Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, Li was Vice President and Head of Oncology at Hengrui, and prior to that, Vice President of Global Strategy at Pfizer. Li’s previous experience also includes Merck and Immunomedics. Li is a trained surgical oncologist who completed fellowship training at the Memorial Sloan Kettering cancer center, and also holds an M.D. from Shandong Medical University and M.B.A. from Fairleigh Dickenson.